| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CD40-TRAF6 interaction; NF-κB
The CD40-TRAF6 inhibitor targets the interaction between CD40 and TRAF6. By binding to TRAF6, it blocks its interaction with CD40. This disrupts CD40-mediated signaling pathways, including the activation of NF-κB. The compound is a cell-permeable small molecule that selectively inhibits the CD40-TRAF6 interaction. |
|---|---|
| ln Vitro |
The CD40-TRAF6 inhibitor suppresses CD40-induced IL-1β and IL-6 expression in macrophages in vitro. It inhibits NF-κB activation in RAW cells. By blocking the CD40-TRAF6 signaling pathway, the compound inhibits classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. These in vitro activities contribute to its anti-atherosclerotic effects.
|
| ln Vivo |
The CD40-TRAF6 inhibitor prevents the progression of established atherosclerosis in mice. It reduces leukocyte recruitment, macrophage activation, and macrophage proliferation in atherosclerotic plaques. The compound improves insulin sensitivity, reduces adipose tissue inflammation, and ameliorates hepatosteatosis in diet-induced obese mice. These in vivo effects highlight its therapeutic potential.
|
| Enzyme Assay |
The CD40-TRAF6 inhibitor's activity is assessed using in vitro binding assays to measure its ability to disrupt the CD40-TRAF6 protein-protein interaction. These assays typically involve techniques such as ELISA, surface plasmon resonance (SPR), or fluorescence polarization to quantify the inhibition of complex formation. The compound's selectivity for CD40-TRAF6 over other TRAF interactions is also evaluated.
|
| Cell Assay |
Cellular assays for the CD40-TRAF6 inhibitor involve treating immune cells (e.g., RAW macrophages) with the compound and measuring NF-κB activation. The compound's ability to suppress CD40-induced IL-1β and IL-6 expression in macrophages is also assessed. These assays evaluate the compound's efficacy in blocking CD40-mediated inflammatory signaling.
|
| Animal Protocol |
In vivo animal model protocols for the CD40-TRAF6 inhibitor involve its administration to mouse models of atherosclerosis and metabolic disease. In atherosclerosis models, the compound's effects on plaque progression, leukocyte recruitment, and macrophage activation are assessed. In diet-induced obese mice, its effects on insulin sensitivity, adipose tissue inflammation, and hepatosteatosis are evaluated.
|
| ADME/Pharmacokinetics |
The CD40-TRAF6 inhibitor has a molecular weight of 251.32 and a molecular formula of C17H17NO. The compound is supplied as a yellow solid powder. It is soluble in DMSO. Specific pharmacokinetic data is not extensively detailed in the available literature, but the compound's efficacy in animal models suggests it has suitable properties for in vivo studies.
|
| Toxicity/Toxicokinetics |
The CD40-TRAF6 inhibitor is intended for research use only and not for human consumption. As a research compound, its comprehensive toxicological profile may not be fully characterized. Standard safety assessments would be required for clinical development. The compound is typically stored as a powder at -20°C for long-term stability.
|
| References | |
| Additional Infomation |
The CD40-TRAF6 inhibitor (CAS# 433249-94-6) is a research compound used to study CD40-TRAF6 signaling and its role in inflammation and atherosclerosis. It is not approved for clinical use. The compound is a potent inhibitor of the CD40-TRAF6 interaction with demonstrated efficacy in preclinical models of atherosclerosis and metabolic disease.
|
| Molecular Formula |
C17H17NO
|
|---|---|
| Molecular Weight |
251.32
|
| Exact Mass |
251.131
|
| Elemental Analysis |
C, 81.24; H, 6.82; N, 5.57; O, 6.37
|
| CAS # |
433249-94-6
|
| Related CAS # |
433249-94-6
|
| PubChem CID |
2291556
|
| Appearance |
Yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
378.6±42.0 °C at 760 mmHg
|
| Flash Point |
133.5±28.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
3.83
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
317
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(/C=C/NC1C=C(C)C=CC=1C)C1C=CC=CC=1
|
| InChi Key |
SARYOFMRLSHZFE-ZHACJKMWSA-N
|
| InChi Code |
InChI=1S/C17H17NO/c1-13-8-9-14(2)16(12-13)18-11-10-17(19)15-6-4-3-5-7-15/h3-12,18H,1-2H3/b11-10+
|
| Chemical Name |
(E)-3-(2,5-dimethylanilino)-1-phenylprop-2-en-1-one
|
| Synonyms |
CD40 TRAF6 inhibitor; CD40-TRAF6 inhibitor; CD40-TRAF6 inhibitor 6877002; TRAF-STOP 6877002; SMI 6877002; SMI6877002; SMI-6877002
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~497.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9790 mL | 19.8950 mL | 39.7899 mL | |
| 5 mM | 0.7958 mL | 3.9790 mL | 7.9580 mL | |
| 10 mM | 0.3979 mL | 1.9895 mL | 3.9790 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
